Company profile
NovelStem International Corp.
OTC: NSTM · Healthcare · Medical - Diagnostics & Research
#915 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
37DFH 51DQ 15GM 34SS 42
v0.1 · 65/100 weight · provisional
↑ return on assets, net margin · ↓ Altman-Z, balance-sheet leverage
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
$2.4M
Employees
2
as of 2026-08-27
Market cap
$493.3k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$616.3k$616.3k2012
Net income$2.4M$2.4M2025
Operating income-$238.8k-$238.8k2025
Total assets$15.8k$15.8k2025
Liabilities$2.2M$2.2M2025
Equity-$2.1M-$2.1M2025
Revenue trend
FY2011 – FY2012 · USD
FY11
FY11
FY12
FY12
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is NovelStem International Corp.’s revenue?
NovelStem International Corp. booked $616.3k in FY2012 revenue, contracting 42% year over year — slower than 79% of Healthcare companies we track, at a 386.1% net margin.
Peers · Healthcare
Comera Life Sciences Holdings, Inc.——CEN Biotech, Inc.——Co-Diagnostics, Inc.33DTheralink Technologies, Inc.——Vaccinex, Inc.——CBD of Denver, Inc.35DNeighbors
Palm Beach →Key facts
CEOJan H. Loeb
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersBoca Raton, FL
ExchangeOTC: NSTM
Employees2
IPO date1993-11-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.